MedTrace Logo

Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy

NCT05995236 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2023-10-23

No results posted yet for this study

Summary

This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.

Conditions

Interventions

DRUG

PSMA radionuclide therapy

Collect clinical data related to treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Alexandru Bageac, MD · Methodist Health System

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-02
Primary Completion
2024-08-02
Completion
2024-08-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05995236 on ClinicalTrials.gov